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Effect of Oral Meloxicam on Health and Performance of Beef Steers
Relative to Bulls Castrated on Arrival at the Feedlot
Abstract
Castration in weaned calves is stressful and affects profitability by reducing ADG and increasing susceptibility
to disease. This study evaluated the effect of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), on
performance and health of calves received as steers compared with bull calves surgically castrated on arrival at
the feedlot. British × Continental bulls (n = 145) and steers (n = 113; BW = 193 to 285 kg) were transported
for 12 h in 3 truckloads (d 0), weighed, and randomly assigned to receive either lactose placebo (CONT; 1
mg/kg) or meloxicam (MEL; 1 mg/kg) suspended in water and administered per os, 24 h before castration.
On d 1, bulls were surgically castrated (CAST) and steers were processed without castration (STR).
Combinations of CONT/MEL and CAST/STR were allocated to 24 pens (6 pens per treatment) of 8 to 14
calves each. Pen was the experimental unit. Plasma meloxicam concentrations at the time of castration (d 1)
were determined by HPLC-mass spectroscopy. Pen-level ADG, DMI, and G:F were estimated using BW
obtained on d 0, 14, and 28 and weigh-back of feed. Individual animals were classified as sick based on a
depression score of ≥2 on a 5-point scale and a rectal temperature of ≥39.8°C. On d 0, 1, and 14, calf chute
temperament was evaluated using a 4-point scale. Data were analyzed using generalized linear mixed models
and survival curve analyses. Castration reduced pen ADG (P < 0.001) and G:F (P < 0.001) from d 1 to 14, yet
no effects (P > 0.45) were apparent by d 28. For all treatment groups, DMI increased with days on feed (P <
0.0001) but was less in CAST compared with STR calves (P < 0.016) throughout the study. From d 15 to 28,
ADG increased (P = 0.0011) in CAST but not STR calves, and G:F decreased (P = 0.0004) in STR but not
CAST calves. In CAST calves only, MEL treatment reduced the pen-level first pull rate (P = 0.04) and
reduced bovine respiratory disease morbidity rate (P = 0.03). The frequency of chute escape behavior was
greater on arrival and at castration in CAST vs. STR calves (P < 0.01) but not significantly different at d 14 (P
= 0.22). Mean MEL concentrations at castration were no different between treated STR and CAST calves (P
= 0.70). Meloxicam administration before castration in postweaning calves reduced the incidence of
respiratory disease at the feedlot. These findings have implications for developing NSAID protocols for use in
calves at castration with respect to addressing animal health and welfare concerns.
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ABSTRACT: Castration in weaned calves is stressful 
and affects profitability by reducing ADG and increas-
ing susceptibility to disease. This study evaluated the 
effect of meloxicam, a nonsteroidal anti-inflammatory 
drug (NSAID), on performance and health of calves 
received as steers compared with bull calves surgically 
castrated on arrival at the feedlot. British × Continen-
tal bulls (n = 145) and steers (n = 113; BW = 193 to 
285 kg) were transported for 12 h in 3 truckloads (d 0), 
weighed, and randomly assigned to receive either lactose 
placebo (CONT; 1 mg/kg) or meloxicam (MEL; 1 mg/
kg) suspended in water and administered per os, 24 h 
before castration. On d 1, bulls were surgically castrat-
ed (CAST) and steers were processed without castra-
tion (STR). Combinations of CONT/MEL and CAST/
STR were allocated to 24 pens (6 pens per treatment) 
of 8 to 14 calves each. Pen was the experimental unit. 
Plasma meloxicam concentrations at the time of castra-
tion (d 1) were determined by HPLC-mass spectros-
copy. Pen-level ADG, DMI, and G:F were estimated us-
ing BW obtained on d 0, 14, and 28 and weigh-back of 
feed. Individual animals were classified as sick based on 
a depression score of ≥2 on a 5-point scale and a rectal 
temperature of ≥39.8°C. On d 0, 1, and 14, calf chute 
temperament was evaluated using a 4-point scale. Data 
were analyzed using generalized linear mixed models 
and survival curve analyses. Castration reduced pen 
ADG (P < 0.001) and G:F (P < 0.001) from d 1 to 14, 
yet no effects (P > 0.45) were apparent by d 28. For all 
treatment groups, DMI increased with days on feed (P 
< 0.0001) but was less in CAST compared with STR 
calves (P < 0.016) throughout the study. From d 15 to 
28, ADG increased (P = 0.0011) in CAST but not STR 
calves, and G:F decreased (P = 0.0004) in STR but not 
CAST calves. In CAST calves only, MEL treatment 
reduced the pen-level first pull rate (P = 0.04) and 
reduced bovine respiratory disease morbidity rate (P 
= 0.03). The frequency of chute escape behavior was 
greater on arrival and at castration in CAST vs. STR 
calves (P < 0.01) but not significantly different at d 
14 (P = 0.22). Mean MEL concentrations at castra-
tion were no different between treated STR and CAST 
calves (P = 0.70). Meloxicam administration before 
castration in postweaning calves reduced the incidence 
of respiratory disease at the feedlot. These findings 
have implications for developing NSAID protocols for 
use in calves at castration with respect to addressing 
animal health and welfare concerns.
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INTRODUCTION
Castration of bulls intended for beef production is a 
common livestock management procedure in the Unit-
ed States (USDA NASS, 2011). Benefits of castration 
include improved meat quality and fewer injuries in 
confinement operations. Nevertheless, castration post-
weaning affects profitability by decreasing ADG and 
increasing susceptibility to bovine respiratory disease 
(BRD; Massey et al., 2011). Although castration is 
considered painful, it is typically performed without 
analgesia (Coetzee et al., 2010). Calls for routine an-
algesic use at castration are increasing due to growing 
public concern about animal welfare (Weary and Fra-
ser, 2004). Currently, no compounds are approved for 
pain relief in cattle and available products may not be 
practical or economical for routine use because drug 
costs are not offset by health or performance benefits 
(Booker et al., 2009; Coetzee et al., 2010). Identifica-
tion of analgesic compounds that may also have perfor-
mance benefits after castration would provide livestock 
producers with an efficient and economically viable way 
to address animal health and welfare concerns.
Previous studies support the hypothesis that extend-
ed exposure to a nonsteroidal anti-inflammatory drug 
(NSAID) may reduce stress and improve performance 
after castration. For example, the NSAID sodium sa-
licylate administered in drinking water for 2 d after 
dehorning and castration reduced serum cortisol after 
surgery and improved ADG over 13 d (Baldridge et 
al., 2011). Meloxicam is an NSAID that is approved in 
Canada for pain relief after disbudding in calves. The 
mean bioavailability of meloxicam after oral adminis-
tration of 1 mg/kg is 100%, and the plasma elimina-
tion half-life in ruminant calves is 27 h (Coetzee et al., 
2009). This suggests that the effects of meloxicam may 
last several days after a single treatment. The objec-
tive of this study was to investigate the effect of oral 
meloxicam administration on performance and health 
of steers and bulls after surgical castration.
MATERIALS AND METHODS
Before the initiation of this experiment, all animal 
use, handling, and sampling techniques described here-
in were approved by the Kansas State University Ani-
mal Care and Use Committee.
Animals, Housing, Treatment Allocation,  
and Processing
This study was designed as a stratified 2-arm parallel 
trial. The strata were calves received as steers (STR) 
vs. calves castrated on arrival (CAST), and the drug 
treatment was meloxicam (MEL) or placebo (CONT; 
Figure 1). Two hundred fifty-eight medium-large frame, 
polled, Continental × British or British crossbred bull 
(CAST; n = 145) and steer (STR; n = 113) calves aged 
8 to 10 mo and weighing 193 to 285 kg were procured 
from sale barns in southeastern Tennessee. Calves were 
shipped approximately 1,086 km to the Kansas State 
University Beef Stocker Unit outside Manhattan, where 
they were housed for the duration of the study. Calves 
were maintained in open pens that consisted of a com-
bination of concrete aprons and dirt pens. Each pen 
was 192 m2 with an allowance of approximately 14 to 
24 m2/animal with 12 m of bunk space and 1 water 
source per pen. A maximum of 14 animals/pen was al-
lowed. Calves arrived at the unit during a 2-wk period 
in March 2010 in 3 loads (lots) of mixed gonadal status 
carrying 83, 87, and 88 calves, respectively. On arrival, 
calves were unloaded and sorted (d 0).
During sorting, calves were individually weighed and 
given an individual identification tag in the right ear. A 
tissue sample for bovine viral diarrhea (BVD) analy-
sis was taken from the left ear using a specialized ear 
notch device (Caisley International GmbH, Bocholt, 
Germany). Ear notch samples were analyzed by antigen 
capture ELISA at the Kansas State University Veteri-
nary Diagnostic Laboratory. All calves were confirmed 
negative for BVD virus. Calves were determined to be 
bulls or steers by palpation and were then randomly 
assigned to either a MEL or CONT-treated group by 
a randomization table generated using Excel (Micro-
soft Corp., Redmond, WA). A total of 71 bulls (MEL-
CAST) and 58 steers (MEL-STR) were scheduled to 
receive meloxicam, whereas 74 bulls (CONT-CAST) 
and 55 steers (CONT-STR) were scheduled to receive 
treatment with the placebo. All steers were assigned to 
STR, namely the uncastrated group, and all bulls were 
allotted to the surgical castration group, CAST. After 
ranking the animals by BW, treatment groups, defined 
as the combination of CONT/MEL and CAST/STR, 
were allocated to 24 pens (6 pens per treatment) of 8 
to 14 calves each, such that pen was recognized as the 
experimental unit.
Meloxicam tablets [Meloxicam tablets USP 15 mg 
(NDC 29300-125-01), Unichem Pharmaceuticals USA 
Inc., Rochelle Park, NJ; lot #GMMH09021] were ad-
ministered at 1 mg of meloxicam/kg of BW per os (PO). 
The dose was rounded down to the nearest whole tablet 
so that no animal received a dose exceeding 1 mg/kg. 
Calves in the placebo-treated group received an equiva-
lent dose of d(+)-lactose monohydrate (Fluka Analyti-
cal, Buchs, Germany), a pharmacologically inactive ex-
cipient used in the manufacture of meloxicam tablets, 
PO. The doses were calculated using arrival BW and 
were administered by suspending crushed meloxicam 
tablets or placebo in approximately 50 mL of water and 
delivering this orally with a dosing syringe within 30 s 
of suspension.
Approximately 24 h after the dosing (d 1), calves 
were brought back through the processing chute and 
given a commercial modified-live, viral respiratory vac-
cine containing infectious bovine rhinotracheitis virus; 
parinfluenzavirus-3; bovine viral diarrhea virus; bo-
vine respiratory syncytial virus; Mannheimia haemo-
lytica (Pyramid 5+ Presponse SQ, Fort Dodge Animal 
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Health, Wyeth, Madison, NJ); a multivalent clostridial 
vaccine (Calvary 9, Intervet/Schering-Plough Animal 
Health, Boxmeer, the Netherlands); injectable ivermec-
tin at 200 µg/kg of BW (Ivomec, Merial Ltd., Duluth, 
GA); and a metaphylactic antimicrobial, ceftiofur crys-
talline free acid at 6.6 mg/kg of BW (Excede, Pfizer 
Animal Health, New York, NY). Products were admin-
istered according to label instructions.
Figure 1. Study outline representing timeline for calves administered lactose placebo (CONT; 1 mg/kg) or meloxicam (MEL; 1 mg/kg, 
Unichem Pharmaceuticals USA Inc., Rochelle Park, NJ) suspended in water per os, 24 h before castration. On d 1, bulls were surgically castrated 
(CAST) and steers were processed without castration (STR).
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Additionally on d 1, castration was performed us-
ing open surgical technique without administration of 
a local anesthetic, consistent with standard industry 
practice in the United States (Coetzee et al., 2010). 
Briefly, the scrotum of each calf was cleaned with dilute 
chlorohexidine disinfectant and incised longitudinally 
with a Newberry knife (Jorgensen Lab, Loveland, CO). 
The testes and spermatic cords were exteriorized by 
blunt dissection, and the cremaster was broken using 
manual traction. The spermatic cords were cut using 
a White’s Double Crush emasculator (Jorgensen Lab) 
applied for approximately 30 s. Steers were subjected 
to the same handling procedures apart from knife cut-
ting and castration. Processing and surgical castration 
was performed by the same operator to minimize varia-
tion in procedure. After processing, calves were sorted 
into study pens.
Calves were reweighed on d 14. Additionally, calves 
were revaccinated with the viral respiratory vac-
cine (Pyramid 5+ Presponse SQ, Fort Dodge Animal 
Health, Wyeth) and given a pour-on eprinomectin at 
500 µg/kg of BW (Eprinex, Merial Ltd.) at this time. 
Final BW was obtained at the end of the study on d 28.
Collection of Samples
Blood samples to confirm meloxicam dosage were 
obtained on d 1 via jugular venipuncture immediately 
after processing. Blood also was collected from the pla-
cebo-treated calves to maintain equality between study 
groups and to ensure that personnel remained masked 
to drug treatment group. Blood samples were collected 
in 6-mL evacuated tubes that contained lithium hepa-
rin (Vacuette plasma tubes, Greiner Bio-One, Monroe, 
NC) and stored on ice for up to 2 h before processing. 
Blood samples were centrifuged for 10 min at 1,500 × g 
at 4°C. Plasma was then harvested, placed in cryovials, 
and frozen at –70°C until analysis. All samples from 
MEL-treated calves were analyzed within 60 d after 
sample collection.
Plasma Meloxicam Analysis
Plasma concentrations of meloxicam (mass:charge ra-
tio [m/z] 352.09→114.90) were determined with HPLC 
(Shimadzu Prominence, Shimadzu Scientific Instru-
ments, Columbia, MD) and mass spectrometry (API 
2000, Applied Biosystems, Foster City, CA). Plasma 
samples or standards (100 µL) were added to 100 µL of 
internal standard (piroxicam 0.5 µg/mL in methanol, 
m/z 332.12→95.10) and 300 µL of methanol with 0.1% 
formic acid to precipitate the proteins. The samples 
were vortex mixed for 5 s and centrifuged for 10 min at 
10,000 × g at 4°C. The supernatant, 200 µL, was trans-
ferred to an injection vial with the injection volume set 
to 10 µL. The mobile phase consisted of A: acetonitrile 
and B: 0.1% formic acid at a flow rate of 0.4 mL/min. 
The mobile phase consisted of 85% B from 0 to 0.5 min 
with a linear gradient to 50% B at 2.5 min, which was 
maintained until 3 min, followed by a linear gradient to 
85% B at 4 min, with a total run time of 5 min. Separa-
tion was achieved with a C8 column (Supelco Discov-
ery C8, 50 mm × 2.1 mm × 5 µm; Sigma-Aldrich, St. 
Louis, MO) maintained at 40°C. The standard curve 
was linear from 0.01 to 10 µg/mL and was accepted if 
the correlation coefficient exceeded 0.99 and predicted 
values were within 15% of the actual values. The ac-
curacy of the assay was 103% ± 7% of the actual value, 
and the CV was 7%, determined on replicates of 5 each 
at 0.025, 0.5, and 5 µg/mL.
Temperament Score
During processing and castration on d 0, 1, and 14, 
animal temperament in the hydraulic squeeze chute was 
evaluated by a single observer masked to drug treat-
ment using a 4-point scale (1 = calm, no movement; 2 
= restless shifting; 3 = squirming, occasional shaking 
of the chute; 4 = continuous vigorous movement and 
shaking of the chute, rearing, twisting, and struggling; 
Voisinet et al., 1997). At each time, animals received a 
single temperament score.
Nutrition Program
Dietary composition is reported on a DM basis. The 
arrival diet consisted of prairie hay containing 7.0% CP 
and 0.44 Mcal of NEg/kg of DM. Beginning 1 d after ar-
rival, the calves were fed a total mixed ration (TMR) 
consisting of prairie hay, alfalfa hay, dry rolled corn, 
wet corn gluten feed, and a commercial premix pellet 
(Cargill Animal Nutrition, Minneapolis, MN). The per-
centage of each ingredient in the diets on an as-fed ba-
sis is presented in Table 1. This ration was formulated 
to contain 15.2% CP and 1.09 Mcal of NEg/kg of DM. 
Beginning 8 d postarrival and continuing through d 18, 
calves were fed a TMR incorporating the same ingredi-
ents as above, but containing 15.2% CP and 1.14 Mcal 
of NEg/kg of DM. On d 19 and continuing through the 
study endpoint, calves were fed a TMR utilizing the 
same ingredients formulated to contain 14.4% CP and 
1.20 Mcal of NEg/kg of DM. Daily feed allowances to 
each pen were recorded. Water was provided for ad libi-
tum intake. Feed bunks were evaluated twice daily, and 
the weight of feed not consumed was used as a basis for 
the amount delivered at the next feeding.
Health Program
Kansas State University Beef Stocker Unit person-
nel conducted twice daily evaluations of the cattle and 
were masked to drug treatment assignment throughout 
the study. Animals were deemed sick based on subjec-
tive criteria including general appearance and attitude, 
gauntness, and reluctance to move. If a sick calf was 
identified, it was removed from the pen, brought to 
the processing unit, and its rectal temperature was ob-
tained.
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To be considered a case of BRD, calves had to dem-
onstrate an absence of abnormal clinical signs attrib-
utable to organ systems other than the respiratory 
system and had to meet the following case definition 
based on presenting clinical signs: 1) observed clinical 
signs of BRD evaluated using a visual depression scor-
ing system (Table 2; Perino and Apley, 1998); a mini-
mum depression score of 2 was required for a diagnosis 
of BRD; and 2) a rectal temperature of >39.8°C (Duff 
and Galyean, 2007).
Calves with visual clinical signs of BRD and a tem-
perature of <39.8°C were not treated. Animals not 
treated for BRD on initial evaluation that continued 
to display clear visual signs of BRD for 2 consecutive 
days were treated with an antimicrobial regardless of 
temperature. All calves that met the treatment criteria 
for BRD were treated with a single subcutaneous (SC) 
dose of 12.5 mg of enrofloxacin/kg (Baytril, Bayer Ani-
mal Health, Shawnee Mission, KS). If the calf met the 
temperature criteria for a second time 72 h postinitial 
treatment, the calf was treated with 40 mg/kg of flo-
rfenicol SC (Nuflor, Intervet/Schering-Plough Animal 
Health). If a calf met the treatment criteria for a third 
time 72 h postsecondary treatment, it received 22 mg/
kg oxytetracycline SC (Biomycin 200, Boehringer In-
gelheim Vetmedica Inc., St. Joseph, MO). After treat-
ments, cattle were returned to their home pens.
In addition to BRD, other health outcomes that 
were considered included lameness, scrotal infection, 
and coccidiosis. A diagnosis of lameness was based on 
signs of limping and reduced weight bearing on 1 or 
more limbs during standing and walking. A diagnosis 
of scrotal infection was based on signs of anorexia, fe-
ver, and the presence of swelling and purulent discharge 
from the castration site. A diagnosis of coccidiosis was 
based on signs of diarrhea, anorexia, and the presence 
of coccidia oocysts on microscopic examination of the 
feces. Calves with lameness and scrotal infections re-
ceived 22 mg of oxytetracycline/kg SC (Biomycin 200, 
Boehringer Ingelheim Vetmedica Inc.), and calves with 
coccidiosis received 10 mg of amprolium/kg PO (Corid 
9.6% oral solution, Merial Ltd.).
The removal of an animal from the study was permit-
ted only for significant illness or injury that compro-
mised the welfare of the animal. All calves that became 
severely injured or moribund were humanely eutha-
nized. Animals that died or were euthanized during the 
study were transferred to the Kansas State University 
Veterinary Diagnostic Laboratory for necropsy and dis-
posal.
Data Collection and Management
All animals were individually weighed on arrival (d 
0), before feeding at revaccination on d 14, and at the 
end of the study on d 28. Time of weighing, scale, and 
weighing conditions were standardized for all animals 
at each time point. Feed consumption for each pen was 
determined on a daily basis by subtracting the weight 
of feed remaining at the next feeding from the total 
feed weight assigned to the pen. When animals were re-
moved for health reasons, the amount of feed delivered 
to the pen and the corresponding animal BW gain in 
the pen were adjusted accordingly so that calculations 
for ADG, DMI, and corresponding G:F were based on 
the number of calves remaining in the pen.
Animal health data recorded for each calf identified 
as sick included the pull date, the individual animal 
Table 1. Dietary components of the rations fed in the study (%, as fed) 
DOF1 Supplement2 Dry-rolled corn WCGF3 Prairie hay Alfalfa hay
1 to 7 3 28 30 16 23
8 to 18 3 29 37 16 15
19 to 28 3 36 37 15 9
1DOF: days on feed.
2Supplement contains 600 g/t of monensin (Elanco Animal Health, Greenfield, IN).
3Wet gluten feed (Sweetbran, Cargill Animal Nutrition, Minneapolis, MN).
Table 2. Depression scoring system used to determine sickness and diagnose bovine respiratory disease (BRD) in 
calves (Perino and Apley, 1998) 
Depression  
score Clinical signs
0 Normal, no signs of depression
1 Noticeable depression without apparent signs of weakness. Slower than pen mates but still raises head when approached and 
does not appear weak; actively follows your movements with a raised head.
2 Marked depression with moderate signs of weakness without a significantly altered gait. Stands with head lowered; will perk 
up when approached but will return to depressed stance; moves slowly and falls toward back of group, may display signs of 
weakness such as incoordination.
3 Severe depression with signs of weakness such as a significantly altered gait. Obviously weak; difficulty in moving with group; 
raises head only when approached closely.
4 Moribund; unable to rise
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identification number, body temperature, clinical score, 
a presumptive diagnosis, BW, and treatment. All data 
were recorded on data capture sheets that were subse-
quently compiled, collated in a computer spreadsheet 
program (Microsoft Office Excel 2007), and verified.
The ancillary production variables [ADG, days on 
feed (DOF), and daily DMI] were calculated for all an-
imals that completed the feeding period. Average daily 
BW gain and pen-level G:F were calculated using the 
following equations (Hannon et al., 2009):
 BW ADG (kg) =
BW d 28 arrival BW (d 0)
DOF
( )−
; 
 
DMI (kg) =
daily pen feed allocation feed remaining at next-  feeding
numberofcalves inthepen
;
 
 BW G:F =
pen level ADG (BW)
pen level DMI
. 
The frequency of the animal health events (pulls, 
overall morbidity, BRD morbidity, re-pulls, and BRD 
relapses) was recorded at pen level and used for statisti-
cal analyses (Hannon et al., 2009).
Statistical Analysis
Health, performance, plasma meloxicam, and behav-
ioral data were analyzed using generalized linear mixed 
models fitted with the GLIMMIX procedure (SAS 
Inst. Inc., Cary, NC). More specifically, performance 
outcomes (DMI, ADG, G:F) and meloxicam concentra-
tions were modeled as Gaussian using an identity link 
function. In turn, the frequency of health events (pull, 
morbidity, BRD) in a given pen were modeled using a 
binomial distribution whereby the number of binomial 
trials was defined by number of animals in a pen. The 
logit link function was used to model health events, 
much as is commonly done with logistic regression. Be-
havior scores were modeled using a categorical multi-
nomial distribution fitted with a cumulative logit link 
function, again as is commonly done with polytomous 
logistic regression. Pen served as the experimental unit 
for all outcomes. Least squares means estimates for 
each treatment group and the corresponding estimated 
SE are reported. Pairwise comparisons were conducted 
using Bonferroni’s method to adjust for multiple com-
parisons and avoid inflation of type I error rate. Sta-
tistical significance for these multiple comparisons was 
designated a priori as a P-value ≤0.05.
For the statistical models on performance outcomes, 
the linear predictor included the fixed effects of gonadal 
status (CAST/STR), drug treatment (MEL/CONT), 
time (d 14 and 28), and all 2- and 3-way interactions. 
Also included in the model were the random blocking 
effect of lot and the random effect of pen to recognize 
the experimental unit for treatment groups. Repeated 
observations within a pen were modeled using a com-
pound symmetry residual variance-covariance struc-
ture. For DMI, the residual variance-covariance was 
expanded to accommodate heterogeneous variances at 
each time period. In turn, for meloxicam concentra-
tions measured 24 h after drug administration, the lin-
ear predictor included the fixed effect of gonadal status 
(CAST/STR) and the random blocking factor of lot. 
For all models fitted on Gaussian responses, Satter-
thwaite method was used to estimate degrees of free-
dom and Kenward-Rogers was used for bias correction 
in SE estimation. Newton-Raphson with ridging was 
the estimation algorithm implemented. Model assump-
tions were evaluated using externally studentized re-
siduals and were considered to be appropriately met.
For health events and for behavioral scores at each 
period of observation, the linear predictor for the sta-
tistical model included the fixed effects of gonadal sta-
tus (CAST/STR), drug treatment (MEL/CONT), and 
their 2-way interaction. Entry BW did not enhance 
model fit and thus was excluded from the final model. 
Table 3. Study removal and mortality rate in calves receiving either lactose placebo 
(CONT; 1 mg/kg) or meloxicam (MEL; 1 mg/kg) suspended in water and administered 
per os, 24 h before processing1 
Item
Experimental group, No. (%)
CAST STR
CONT MEL CONT MEL
Number enrolled 74 71 55 58
Completed study 73 67 53 57
Study removal 1 (1%) 4 (6%) 2 (4%) 1 (2%)
Mortality rate 0 0 1 (2%) 0
Reason for removal     
 Lameness 1 (1%) 2 (3%) 1 (2%) 1 (2%)
 Chronic coccidiosis 0 1 (1%) 0 0
 Neurological symptoms 0 1 (1%) 0 0
 Pen death 0 0 1 (2%) 0
1On d 1, bulls were surgically castrated (CAST) and steers were processed without castration (STR).
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The random effect of lot was also fit in the linear pre-
dictor as a blocking factor to account for variability 
in health events between lots. In addition, pen nested 
within gonadal status and drug treatment was incorpo-
rated in the linear predictor to recognize pen as the ex-
perimental unit for these factors. For binomial respons-
es, inference was conducted after checking for absence 
of overdispersion based on the Pearson χ2/degrees of 
freedom fit statistic. Model parameters were estimated 
using Laplace integral approximation to maximum like-
lihood.
Kaplan-Meier plots for cumulative pull rate, crude 
morbidity, and BRD morbidity for CAST and STR 
groups were generated using GraphPad Prism (Graph-
Pad Software, La Jolla, CA). The endpoint of inter-
est was survival time, which was defined as the time 
to first pull, first treatment, first treatment for BRD, 
or the end of the study in days. In the data set, the 
variable group represented the drug treatment category 
(MEL or CONT), the variable time represented the 
disease-free survival time, and the variable status was 
used as a censoring indicator, with the value 1 indicat-
ing an event time and the value 0 indicating a censored 
time. We identified group as strata and tested the null 
hypothesis that the 2 groups had equal survival curves 
using the log-rank (Mantel-Cox) test. If the P-value for 
the log-rank test was <0.05, this was evidence to reject 
the null hypothesis. The slope of the curve was used to 
compute a hazard ratio and its confidence interval us-
ing the Mantel Haenszel approach to compare the rate 
of an event occurring in the 2 treatments over time.
RESULTS
After randomization, the mean (±SD) BW was 
248.32 ± 16.20 kg in the CONT-CAST group, 247.66 
± 16.90 kg in the MEL-CAST group, 245.04 ± 15.02 
kg in the CONT-STR group, and 244.72 ± 15.65 kg in 
the MEL-STR group, respectively. After 28 d, 73 of 74 
calves in the CONT-CAST group, 67 of 71 calves in 
the MEL-CAST group, 53 of 55 calves in the CONT-
STR group, and 57 of 58 calves in the MEL-STR group 
completed the study. One calf in the CONT-STR group 
died from necrotizing diffuse phlebitis of the external il-
iac and femoral veins with associated thrombo-embolic 
pneumonia. Lameness accounted for removal of 1 calf 
from the CONT-CAST, CONT-STR, and MEL-STR 
groups, respectively, and 2 calves from the MEL-CAST 
group (Table 3). One calf was removed from the MEL-
CAST group with chronic coccidiosis, and another was 
removed with neurological symptoms.
Performance
Based on evidence for a sex × DOF interaction (P 
= 0.0022), ADG of CAST calves was less than those of 
STR calves only at 14 d, but no evidence (P = 0.45) 
for a difference was apparent at 28 d (Table 4). There 
was no evidence of an effect of MEL administration (P T
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= 0.972) on ADG. The CAST calves had a 0.65 ± 0.17 
kg/d increase in ADG from d 15 to 28 compared with 
d 1 to 14 (P = 0.0011). In contrast, STR calves had a 
0.20 ± 0.17 kg/d decrease in ADG over the correspond-
ing period, but this was not significantly different from 
zero (P = 0.26). Furthermore, STR calves had a 0.74 
± 0.14 kg/d greater ADG between d 1 and 14 (P < 
0.001) compared with CAST calves, but evidence for 
this difference was not apparent between d 15 and 28 
(P = 0.45).
Regardless of MEL treatment, pen-level DMI was less 
in CAST calves than in STR calves (P = 0.016; Table 
4). In either gonadal group, there was no evidence for 
an effect of MEL administration (P = 0.73) on DMI. 
However, DMI was greater at d 28 compared with d 14 
in both CAST and STR calves (P < 0.001) irrespective 
of treatment.
There was no evidence of an effect of MEL adminis-
tration (P = 0.73) on G:F (Table 4). Regardless of MEL 
treatment, CAST calves showed no evidence for a dif-
ference in G:F from d 15 to 28 compared with d 1 to 14 
(P = 0.16). In contrast, STR calves had a 0.12 ± 0.03 
kg/d decrease in G:F over the corresponding period (P 
= 0.0004). Furthermore, STR calves had a 0.13 ± 0.02 
greater G:F between d 1 and 14 (P < 0.001) compared 
with CAST calves but evidence for this difference was 
not apparent between d 15 and 28 (P = 0.31).
Health
The pen-level first pull rate was greater in the CONT-
CAST (45.19 ± 11.1%) compared with the MEL-CAST 
(25.83 ± 9.0%) calves (P = 0.038; Table 5). Pull rate in 
STR calves was not significantly different between the 
2 drug treatments (P = 0.78). However, pull rate was 
greater in the CONT-CAST calves compared with the 
CONT-STR calves (P = 0.007) but not significantly dif-
ferent between the MEL-CAST and MEL-STR calves 
(P = 0.43). The overall case distribution is presented in 
Figure 2a and b. Overall morbidity rate was marginally 
greater in CAST calves than in STR calves regardless 
of treatment (P = 0.08). No evidence for treatment dif-
ferences on overall morbidity was apparent (P = 0.28).
The incidence of BRD was marginally greater in 
CAST calves than STR calves (P = 0.06), but there 
was no evidence for a difference in overall morbidity at-
tributable to BRD between MEL treatment groups (P 
= 0.31). The incidence of BRD was greater in CONT-
CAST compared with MEL-CAST calves (P = 0.003) 
but not significantly different between CONT-STR and 
MEL-STR calves (P = 0.67). Morbidity was greater in 
the CONT-CAST compared with CONT-STR calves 
(P = 0.0006), but there was no evidence for a differ-
ence between the MEL-CAST and MEL-STR calves (P 
= 0.68).
The first re-pull rate was not significantly different 
between CAST and STR calves (P = 0.14) or between 
drug treatment groups (P = 0.99). First BRD retreat-
ment rate was not significantly different between sex 
(P = 0.60) and drug treatment (P = 0.70; Table 6). 
There was also no evidence for a difference between 
CAST and STR calves (P = 0.66) or treatment groups 
(P = 0.64) for calves pulled a third time. Similarly, the 
third BRD treatment rate did not differ significantly 
between CAST and STR calves (P = 0.37) or between 
drug treatment (P = 0.94).
Log-rank (Mantel-Cox) tests indicated that placebo-
treated and MEL-treated calves had dissimilar survival 
curves for first pull rate, overall morbidity rate, and 
BRD morbidity rate (P = 0.004; Figure 3a and b; Table 
7). Furthermore, survival curve comparisons for first 
pull rate and BRD morbidity rate indicated a greater 
hazard ratio between MEL-CAST and CONT-CAST 
calves (P = 0.016) and CONT-CAST and CONT-STR 
Table 5. Estimated probability of health events (±SEM) adjusted for pen in bulls castrated on arrival (CAST) 
and steers (STR) receiving either lactose placebo (1 mg/kg) or meloxicam (1 mg/kg) suspended in water and ad-
ministered per os, 24 h before processing1 
Item
Experimental group
P-valueCAST STR
Placebo Meloxicam Placebo Meloxicam Sex Trt2 Sex × Trt
Population at risk 74 71 55 58    
Pulls, % 45.2a,x 25.8y 19.7b 17.1 0.01 0.06 0.45
(11.1) (9.0) (6.0) (8.7)
Overall morbidity, % 35.0a 21.1 13.3b 14.4 0.07 0.28 0.36
(16.5) (12.1) (8.6) (10.8)
Bovine respiratory disease morbidity, % 33.8a,x 17.2y 9.7b 12.6 0.06 0.31 0.21
(15.4) (10.7) (5.8) (10.2)
a,bIndicate differences between bulls and steers treated with placebo (P < 0.05). No evidence for differences was apparent among calves treated 
with meloxicam.
x,yIndicate differences in bulls treated with placebo vs. meloxicam (P < 0.05). No evidence for differences between placebo and meloxicam was 
apparent in steers.
1On d 1, bulls were surgically castrated and steers were processed without castration.
2Trt: treatment (Meloxicam or placebo).
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Figure 2. Morbidity distribution pattern in bulls (panel A) and steers (STR; panel B) administered lactose placebo (CONT; 1 mg/kg) or 
meloxicam (MEL; 1 mg/kg, Unichem Pharmaceuticals USA Inc., Rochelle Park, NJ) suspended in water per os, 24 h before castration (CAST). 
BRD = bovine respitory disease.
Table 6. Estimated probability of re-treatment health events (±SEM) adjusted for pen in bulls castrated on ar-
rival (CAST) and steers (STR) receiving either lactose placebo (1 mg/kg) or meloxicam (1 mg/kg) suspended in 
water and administered per os, 24 h before processing1 
Item
Experimental group
P-valueCAST STR
Placebo Meloxicam Placebo Meloxicam Sex Trt2 Sex × Trt
First re-pull rate, % 43.7 52.6 27.1 69.9 0.14 0.99 0.31
(14) (8) (16) (21)
First bovine respiratory disease relapse rate, % 33.3 35.7 33.3 50.0 0.60 0.70 0.70
(12) (14) (22) (20)
1On d 1, bulls were surgically castrated and steers were processed without castration.
2Trt: treatment (meloxicam or placebo). Meloxicam: Unichem Pharmaceuticals USA Inc., Rochelle Park, NJ.
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calves (P = 0.003). Other survival curve comparisons 
for first pull rate and BRD morbidity rate were not sig-
nificantly different (P > 0.2). A hazard ratio that ap-
proached statistical significance (P = 0.073) was iden-
tified for overall morbidity rate between MEL-CAST 
and CONT-CAST groups, and a hazard ratio occurred 
between CONT-CAST and CONT-STR groups (P = 
0.003). Other survival curve comparisons were not sig-
nificantly different (P > 0.2).
Behavior
At the time of dosing with meloxicam (d 0), the 
relative frequency of temperament score 1 was greater 
among STR than CAST calves (P = 0.0019; Figure 
4), thus indicating calmer temperament in the former. 
This difference between STR and CAST calves was also 
apparent at castration (d 1), whereby CAST calves 
showed more frequent escape behaviors recorded than 
STR calves (P < 0.001). However, evidence for these 
differences was not apparent at revaccination, which is 
14 d after castration (P = 0.22). Moreover, there was 
no evidence for differences in behavior between MEL 
and CONT calves at any of the time points evaluated 
(P > 0.35).
Meloxicam Concentrations
The administered dose of meloxicam rounded down 
to the nearest whole tablet ranged from 0.89 to 1.00 
mg/kg. Sorting and drug administration commenced at 
around 0800 h and was concluded by 1030 h and there-
fore lasted approximately 2 min per calf. The mean 
(±SEM) plasma meloxicam concentration at the time 
of castration, approximately 24 h after treatment, was 
6.01 ± 0.07 µg/mL in CAST and 5.97 ± 0.07 µg/mL in 
STR calves (P = 0.70; Figure 5). No outward adverse 
events associated with NSAID administration (e.g., 
gastrointestinal bleeding, clotting deficits, or anorexia) 
were noted after PO administration of meloxicam.
DISCUSSION
Castration of male calves destined for beef produc-
tion is one of the most common livestock management 
practices performed in the United States, amounting 
to approximately 7 million procedures per year (USDA 
NASS, 2011). It is estimated that 41% of beef opera-
tions in the United States do not castrate bull calves 
before sale and approximately 1 of 5 operations (18.4%) 
do not castrate calves until they are over 122 d old 
(USDA, 2008). Castration in weaned calves is stress-
ful and affects profitability by reducing performance 
and increasing susceptibility to disease, especially BRD 
(Massey et al., 2011). Bovine respiratory disease con-
trol in highly stressed cattle is predicated on the ad-
ministration of vaccines and prophylactic antimicro-
bials; however, these may be ineffective in preventing 
disease outbreaks in high-risk cattle (Duff and Galyean, 
2007). To our knowledge, this study is the first to test 
the hypothesis that oral administration of meloxicam, 
an NSAID with a long plasma elimination half-life, at 
the time of castration, may improve the health and 
performance of calves after castration.
A review by Bretschneider (2005) found that castra-
tion-associated BW loss reported in the published lit-
erature increased quadratically with age. In this review, 
a mean reduction in DMI of 20.5 ± 5% was reported in 
the published reports during the first 2 wk after surgi-
cal castration in 5-mo-old calves. Massey et al. (2011) 
Figure 3. Kaplan-Meier survival curve depicting cumulative pull 
rate (panel A) and bovine respiratory disease (BRD) treatment rate 
(panel B) in calves administered lactose placebo (CONT; 1 mg/kg) or 
meloxicam (MEL; 1 mg/kg, Unichem Pharmaceuticals USA Inc., Ro-
chelle Park, NJ) per os, suspended in water, 24 h before castration. On 
d 1, bulls were surgically castrated (CAST) and steers were submitted 
to processing without castration (STR). First pull rate was significant-
ly greater in CONT-CAST calves compared with MEL-CAST calves 
(P = 0.016) and CONT-STR calves (P = 0.0029). The BRD morbidity 
rate was significantly greater in CONT-CAST calves compared with 
MEL-CAST calves (P = 0.0230) and CONT-STR calves (P = 0.0009).
1035Effect of meloxicam after bovine castration
evaluated records for 2,190 bulls and 1,190 steers and 
calculated an average ADG of 1.55 kg/d in steers (cas-
trated prearrival) and 1.32 kg/d in bulls (castrated 
postarrival). The results of the present study report a 
similar decrease in performance in CAST calves over 
14 d after castration. However, from d 14 to 28 there 
was evidence of compensatory growth in the castrated 
calves. The timeframe of performance loss suggests 
that this was likely associated with reduced frequency 
of feeding and watering bouts in castrated calves rath-
er than testosterone withdrawal (Daniels et al., 2000; 
Bretschneider, 2005).
Administration of the NSAID ketoprofen before sur-
gical castration increased feeding and rumination ac-
tivities and reduced pain-associated behaviors in treat-
ed calves compared with untreated controls (Ting et 
al., 2003). Earley and Crowe (2002) demonstrated that 
calves receiving ketoprofen combined with local anes-
thesia before surgical castration had a greater ADG 
during the 35 d after castration compared with untreat-
ed calves. However, an increase in DMI or improved 
G:F was not reported. Baldridge et al. (2011) found 
that calves receiving 2.5 to 5 mg of sodium salicylate/
mL of drinking water beginning 72 h before concur-
rent surgical castration and dehorning and continuing 
for 48 h after surgery had a greater ADG during the 
13 d after concurrent castration and dehorning than 
untreated calves. Although these findings support the 
hypothesis that extended exposure to an NSAID may 
improve growth and performance after castration, this 
was not observed after meloxicam administration in the 
present study. Studies evaluating the effect of meloxi-
cam on individual animal feeding behavior and intakes 
after castration are needed to fully assess drug effects.
In the present study, calves in the CONT-CAST 
group were at greater risk of being identified as requir-
ing treatment for disease compared with CONT-STR 
calves. Pinchak et al. (2004) reported 60% morbidity in 
stocker calves (average BW = 216 kg) castrated after 
arrival compared with 28% morbidity in cohort steers. 
Berry et al. (2001) reported a 93% pull rate in bulls 
castrated on arrival compared with a 50% pull rate in 
calves received as steers. Furthermore, 59% of castrated 
calves were treated at least once compared with 33% of 
steers in this study. Of calves castrated on arrival, 23% 
were retreated. Daniels et al. (2000) found that calves 
castrated on arrival at a feedlot (BW = 158 ± 14 kg) 
had a 36% incidence of morbidity compared with 19% 
morbidity in calves received as steers. This is similar to 
the morbidity rate reported in the present study in the 
CONT-CAST calves.
The risk of local or systemic disease after castration 
is increased by stress and postsurgical immunosuppres-
sion (Earley and Crowe, 2002). Surgical castration is 
associated with increased circulating cortisol and hap-
toglobin concentrations and decreased gamma-interfer-
on production (Fisher et al., 1997; Earley and Crowe, 
2002). An increase in cortisol and haptoglobin causes 
a suppression of lymphocyte function and a decrease 
in gamma-interferon is associated with impaired cell-
mediated immunity and reduced response to antigens. 
Earley and Crowe (2002) found that administration of 
ketoprofen decreased cortisol and haptoglobin concen-
trations and prevented suppression of the gamma-inter-
feron response. This finding suggests that ketoprofen 
administration may reduce immunosuppression associ-
ated with surgical castration, and it could be hypoth-
esized that other NSAID, such as meloxicam, may have 
similar effects. This may explain why the incidence of 
BRD in MEL-CAST was significantly less than in the 
CONT-CAST group in the present study; however, 
studies specifically designed to evaluate the effect of 
meloxicam on immune function after castration are 
needed to assess this further.
Table 7. Log-rank (Mantel-Cox) and Mantel Haenszel hazard ratio comparison between cumulative incidence of 
first pull, overall morbidity, and bovine respiratory disease (BRD) morbidity in calves receiving either lactose pla-
cebo (CONT; 1 mg/kg) or meloxicam (MEL; 1 mg/kg, Unichem Pharmaceuticals USA Inc., Rochelle Park, NJ) 
suspended in water and administered per os, 24 h before castration1 
Item Log-rank χ2 P-value Survival curve comparison
Hazard 
ratio
95% CI
P-value
Lower 
(HR)
Upper 
(HR)
First pull rate 16.73 0.0008 CONT-CAST vs. MEL-CAST 1.97 0.016
   MEL-STR vs. CONT-STR 1.18 0.50 2.79 0.71
MEL-CAST vs. MEL-STR 1.59 0.76 3.32 0.244
CONT-CAST vs. CONT-STR 2.48 1.37 4.51 0.0029
Overall morbidity rate 13.26 0.0041 CONT-CAST vs. MEL-CAST 1.73 0.95 3.16 0.073
   MEL-STR vs. CONT-STR 0.83 0.31 2.22 0.71
MEL-CAST vs. MEL-STR 1.58 0.72 3.43 0.25
CONT-CAST vs. CONT-STR 2.86 1.44 5.68 0.003
BRD morbidity rate 16.89 0.0007 CONT-CAST vs. MEL-CAST 2.06 1.11 3.82 0.023
   MEL-STR vs. CONT-STR 0.78 0.27 2.23 0.64
MEL-CAST vs. MEL-STR 1.49 0.64 3.47 0.36
CONT-CAST vs. CONT-STR 3.23 1.62 6.45 0.0009
1On d 1, bulls were surgically castrated (CAST) and steers were submitted to simulated castration (STR). CI = confidence interval; HR = 
hazard ratio.
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Meloxicam is an NSAID of the oxicam class that is 
approved in the European Union for adjunctive ther-
apy of acute respiratory disease, diarrhea, and acute 
mastitis when administered at 0.5 mg/kg intravenously 
(IV) or SC (EMEA, 2009). Although studies reporting 
health and performance benefits after NSAID adminis-
tration before castration are deficient in the published 
literature, meloxicam administration has been associ-
ated with improved ADG in calves treated for clinical 
BRD (Friton et al., 2005). Recently, meloxicam was 
approved in Canada as an aid in improving appetite 
and BW gains when administered at the onset of diar-
rhea and for relief of pain after disbudding of horn buds 
in calves less than 3 mo of age. Heinrich et al. (2009) 
demonstrated that 0.5 mg of meloxicam/kg intramus-
cularly combined with a cornual nerve block reduced 
Figure 4. Estimated cumulative probabilities of temperament scores in bulls and steers at arrival (d 0), castration (d 1), and 14 d after cas-
tration. Animals were receiving either lactose placebo (P; 1 mg/kg) or meloxicam (M; 1 mg/kg, Unichem Pharmaceuticals USA Inc., Rochelle 
Park, NJ) suspended in water and administered per os, 24 h before processing with or without castration. Temperament scores are 1 = calm, no 
movement; 2 = restless shifting; 3 = squirming, occasional shaking of the chute; 4 = continuous vigorous movement and shaking of the chute, 
rearing, twisting, and struggling.
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serum cortisol response longer compared with calves 
receiving only local anesthesia before cautery dehorn-
ing. This suggests that meloxicam may mitigate pain 
and distress associated with painful procedures such 
as castration similar to what has been reported after 
ketoprofen administration (Earley and Crowe, 2002).
The pharmacokinetics of meloxicam after PO and IV 
administration have been described recently (Coetzee 
et al., 2009, 2011). A mean peak plasma concentra-
tion of 3.10 ug/mL (range: 2.64 to 3.79 ug/mL) was 
recorded at 11.64 h (range: 10 to 12 h) with a half-life 
of 27.54 h (range: 19.97 to 43.29 h) after oral meloxi-
cam administration at 1 mg/kg (Coetzee et al., 2009). 
Based on these data, meloxicam was administered 24 
h before castration in the present study to ensure that 
peak plasma drug concentrations were achieved before 
the onset of tissue damage. It is noteworthy that the 
mean plasma meloxicam concentration at the time of 
castration was greater in the present study than previ-
ously reported. This is likely due to the fact that feed 
was not withheld from calves in the pharmacokinetics 
study before dosing, which likely delayed drug absorp-
tion (Coetzee et al., 2009). Calves in the present study 
had been shipped over 12 h before treatment and the 
rumen was likely relatively empty, which probably re-
duced the amount of drug binding to feed.
Nonsteroidal anti-inflammatory drugs produce anal-
gesia and reduce inflammation by inhibiting the en-
zyme cyclooxygenase and subsequent PG production 
in the peripheral tissues and central nervous system 
(Ochroch et al., 2003). Surgery-induced pain consists 
of 2 phases: an immediate incisional phase and a pro-
longed inflammatory phase that arises primarily due 
to tissue damage (Kissin, 2000; Gottschalk and Smith, 
2001). The goal of administering MEL to calves before 
processing was principally to mitigate pain associated 
with inflammation after castration because NSAID 
do not produce effects that would significantly reduce 
acute, incisional pain. This explains why temperament 
scores were similar in MEL-treated and placebo-treated 
CAST calves in this study. In the present report, CAST 
calves demonstrated behavior causing more shifting 
and shaking of the chute than STR calves on arrival 
and during castration. This likely reflects temperament 
differences between CAST and STR related to prior 
handling events and also distress associated with the 
castration procedure.
The connection between meloxicam administration 
and health benefits observed in bull calves castrated on 
arrival may be partially supported by the lack of evi-
dence of analogous treatment effect in calves processed 
as steers. We speculate that this is due to the prolonged 
anti-inflammatory properties of meloxicam mitigating 
the negative health effects of inflammation after surgi-
cal castration, but further investigation is needed to 
clarify this association further.
Meloxicam administered to cattle by any route con-
stitutes extra-label drug use because currently no an-
algesic drugs are specifically approved to provide pain 
relief in livestock in the United States (Smith et al., 
2008). Under the Animal Medicinal Drug Use Clarifica-
tion Act (AMDUCA), extra-label drug use is permit-
ted under veterinary supervision for relief of suffering 
in cattle provided specific conditions are met (US Food 
and Drug Administration, 1994). Meloxicam injection 
(20 mg/mL) is approved for use in cattle in the Europe-
an Union with a 15-d meat withdrawal and in Canada 
with a 20-d meat withdrawal time after administration 
of 0.5 mg/kg IV or SC. Several generic tablet formula-
tions containing meloxicam (7.5 and 15 mg) have been 
approved for relief of signs and symptoms of osteoar-
thritis in human medicine. These formulations were 
used in the present study with a cost of US $0.30/100 
kg of BW. In the absence of FDA-approved analgesic 
compounds in food animals, use of oral meloxicam tab-
lets for alleviation of pain in cattle can be considered 
under AMDUCA.
The results of this study suggest that castration re-
duced pen-level performance from d 1 to 14, but there 
was no evidence for an effect of NSAID treatment on 
BW gain or feed intake. Meloxicam administration re-
duced the pen-level health events in CAST calves, but 
there was no evidence for meloxicam effects on health 
events in STR calves. These findings suggest that 
meloxicam administration before castration in post-
weaning calves may decrease the number of castrated 
calves requiring antimicrobial therapy for pneumonia 
and lessen the economic impact of BRD in livestock 
production systems. These results have implications for 
developing pain mitigation strategies involving NSAID 
in calves at castration with respect to addressing both 
animal health and welfare concerns.
Figure 5. Box and whisker graph showing the median, 25th and 
75th percentile, and range of plasma meloxicam (Unichem Pharma-
ceuticals USA Inc., Rochelle Park, NJ) concentrations at the time 
of castration in calves administered 1 mg/kg of meloxicam per os in 
water, 24 h before castration (MEL-CAST), or processing without 
castration (MEL-STR).
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